Gina N Woods1,2, Mei-Hua Huang3, Peggy M Cawthon4, Corinne McDaniels-Davidson1, Howard A Fink5,6,7, Deborah M Kado1. 1. University of California, San Diego, La Jolla, CA. 2. VA San Diego Healthcare System, San Diego, CA. 3. David Geffen School of Medicine at UCLA, Los Angeles, CA. 4. California Pacific Medical Center Research Institute, San Francisco, CA. 5. Geriatric Research Education and Clinical Center, Veterans Affairs Health Care Center, Minneapolis, MN. 6. Center for Chronic Disease Outcomes Research, Veterans Affairs Health Care Center, Minneapolis, MN. 7. Department of Medicine, and Division of Epidemiology and Community Health School of Public Health, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: Hyperkyphosis, an exaggerated anterior curvature of the thoracic spine, is associated with poor physical function, falls, fractures, and earlier mortality. Low bone mineral density, bone loss, and vertebral fractures are strong risk factors for hyperkyphosis. Menopausal hormone therapy (HT) reverses bone loss, prevents vertebral fractures, and, therefore, we hypothesize, may reduce the risk for developing hyperkyphosis. METHODS: We evaluated the cross-sectional association between Cobb angle of kyphosis from lateral spine radiographs and pattern of self-reported HT use during the prior 15-year period in 1,063 women from the Study of Osteoporotic Fractures. RESULTS: Participants had a mean age of 83.7 ± 3.3 years and a mean Cobb angle of 51.3 ± 14.6°. Forty-six per cent of women were characterized as never-users of HT, 24% as remote past users, 17% as intermittent users, and 12% as continuous users. In minimally adjusted models, the mean Cobb angle was 4.0° less in continuous HT users compared with never-users (P = 0.01); however, in fully adjusted models, this association was attenuated to 2.8° (P = 0.06). Remote past HT users had 3.0° less kyphosis compared with never-users in minimally adjusted models (P = 0.01), attenuated to 2.8° less in fully adjusted models (P = 0.02). Intermittent users did not differ from never-users in degree of kyphosis. CONCLUSIONS: Women reporting continuous or remote past HT use had less pronounced kyphosis than never-users by their mid-eighties, suggesting a possible role for HT in the prevention of age-related hyperkyphosis.
OBJECTIVE:Hyperkyphosis, an exaggerated anterior curvature of the thoracic spine, is associated with poor physical function, falls, fractures, and earlier mortality. Low bone mineral density, bone loss, and vertebral fractures are strong risk factors for hyperkyphosis. Menopausal hormone therapy (HT) reverses bone loss, prevents vertebral fractures, and, therefore, we hypothesize, may reduce the risk for developing hyperkyphosis. METHODS: We evaluated the cross-sectional association between Cobb angle of kyphosis from lateral spine radiographs and pattern of self-reported HT use during the prior 15-year period in 1,063 women from the Study of Osteoporotic Fractures. RESULTS:Participants had a mean age of 83.7 ± 3.3 years and a mean Cobb angle of 51.3 ± 14.6°. Forty-six per cent of women were characterized as never-users of HT, 24% as remote past users, 17% as intermittent users, and 12% as continuous users. In minimally adjusted models, the mean Cobb angle was 4.0° less in continuous HT users compared with never-users (P = 0.01); however, in fully adjusted models, this association was attenuated to 2.8° (P = 0.06). Remote past HT users had 3.0° less kyphosis compared with never-users in minimally adjusted models (P = 0.01), attenuated to 2.8° less in fully adjusted models (P = 0.02). Intermittent users did not differ from never-users in degree of kyphosis. CONCLUSIONS:Women reporting continuous or remote past HT use had less pronounced kyphosis than never-users by their mid-eighties, suggesting a possible role for HT in the prevention of age-related hyperkyphosis.
Authors: Deborah M Kado; Lisa Christianson; Lisa Palermo; Rebecca Smith-Bindman; Steven R Cummings; Gail A Greendale Journal: Spine (Phila Pa 1976) Date: 2006-02-15 Impact factor: 3.468
Authors: Nelson B Watts; Jane A Cauley; Rebecca D Jackson; Andrea Z LaCroix; Cora E Lewis; JoAnn E Manson; Joan M Neuner; Lawrence S Phillips; Marcia L Stefanick; Jean Wactawski-Wende; Carolyn Crandall Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958
Authors: Deborah M Kado; Dana Miller-Martinez; Li-Yung Lui; Peggy Cawthon; Wendy B Katzman; Teresa A Hillier; Howard A Fink; Kristine E Ensrud Journal: J Bone Miner Res Date: 2014-10 Impact factor: 6.741
Authors: Deborah M Kado; Mei-Hua Huang; Elizabeth Barrett-Connor; Gail A Greendale Journal: J Gerontol A Biol Sci Med Sci Date: 2005-05 Impact factor: 6.053
Authors: Deborah M Kado; Mei-Hua Huang; Arun S Karlamangla; Peggy Cawthon; Wendy Katzman; Teresa A Hillier; Kristine Ensrud; Steven R Cummings Journal: J Bone Miner Res Date: 2013-01 Impact factor: 6.741
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Cynthia A Stuenkel; Susan R Davis; Anne Gompel; Mary Ann Lumsden; M Hassan Murad; JoAnn V Pinkerton; Richard J Santen Journal: J Clin Endocrinol Metab Date: 2015-10-07 Impact factor: 5.958
Authors: Richard D Wasnich; Yu Z Bagger; David J Hosking; Michael R McClung; Mei Wu; Ann Marie Mantz; John J Yates; Philip D Ross; Peter Alexandersen; Pernille Ravn; Claus Christiansen; Arthur C Santora Journal: Menopause Date: 2004 Nov-Dec Impact factor: 2.953